A Clinical Study of 9MW2821 in Subjects With Advanced Malignant Solid Tumors
Status:
Not yet recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
This study is a Phase 1/2, first-in-human, open-label, dose-escalation and cohort expansion
study designed to characterize the safety, tolerability, pharmacokinetics, preliminary
antitumor activity and immunogenicity of 9MW2821 administered by intravenous (IV) infusion.